Agios Pharmaceuticals (AGIO) Stock Price, Quote & News

Company Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatr...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 649 8600

Website: www.agios.com

Address:

88 Sidney Street, Cambridge, United States

stu4 Feb. 23 at 11:04 AM

$AGIO another loser , chasing biotech misfits at AGIOS

0 · Reply

StockConsultant Feb. 23 at 4:22 AM

$AGIO Agios Pharmaceuticals stock, strong close, watch for an upside gap breakout at https://stockconsultant.com/?AGIO

0 · Reply

Dkll303 Feb. 21 at 11:50 AM

$AGIO good thing you clarified your synopsis. Bellevenue sold out of this pos, after 6 years , 3.9M shares A 40M dollar loss !!!

0 · Reply

OfficialStocktwitsUser Feb. 20 at 10:54 PM

$AGIO RSI: 64.86, MACD: 0.0838 Vol: 0.73, MA20: 27.87, MA50: 27.45 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

stu4 Feb. 19 at 2:09 PM

$RYTM RBC ..says buy , hahaha …they said that at $AGIO and target was $75 …then the Nov 19, 2025 crash …and $28 That analyst is a zero for biotech, matching Butt Boy Behrens at Leerick partners , where they fcuked up and went bankrupt

0 · Reply

BillionerOfKing Feb. 19 at 10:37 AM

$AGIO Current Stock Price: $27.54 Contracts to trade: $30.0 AGIO Feb 20 2026 Call Entry: $0.05 Exit: $0.07 ROI: 50% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

freddie04 Feb. 13 at 7:26 PM

$AGIO ahhhhh , ohhhhh looks like FOUSE LIED TO SHAREHOLDERS ONCE AGAIN … They need more money to keep their jobs and SUCK YOU DRY with NO VALUE EVER CREATED FOR YOU SHAREHOLDERS

0 · Reply

freddie04 Feb. 13 at 7:24 PM

$AGIO ..Jackie Fouse states : on their own website !!! “ no need to raise cash “ Well…..guess the fcuk what ? SHE LIED ! Like GOFF and the submission of Thalassemia dec2024 , they were liver issues !!! The whole company is full of LIARS

0 · Reply

freddie04 Feb. 13 at 7:22 PM

$AGIO NO WE HAVE THIS 2/12/26 stated in 2022 “ plenty of cash “ several years is a decade , NOT 4 years They are losers here

0 · Reply

freddie04 Feb. 13 at 7:21 PM

$AGIO ONCE A LIAR, ALWAYS A LIAR FOUSE On RAISING CASH !

0 · Reply

Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript

Feb 12, 2026, 6:30 AM EST - 11 days ago

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Jan 26, 2026, 7:00 AM EST - 4 weeks ago

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

Jan 14, 2026, 2:36 PM EST - 5 weeks ago

Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:00 AM EST - 6 weeks ago

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

Jan 5, 2026, 7:00 AM EST - 7 weeks ago

Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 24, 2025, 4:56 PM EST - 2 months ago

Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript

Dec 24, 2025, 12:48 PM EST - 2 months ago

Agios Pharma Stock: A Buy After FDA Approves Aqvesme

Dec 24, 2025, 9:56 AM EST - 2 months ago

Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

Dec 24, 2025, 8:22 AM EST - 2 months ago

Agios Pharma shares jump as US FDA expands approval for its blood disorder drug

Dec 23, 2025, 7:45 PM EST - 2 months ago

U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

Dec 8, 2025, 7:00 AM EST - 2 months ago

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

Nov 19, 2025, 2:33 PM EST - 3 months ago

Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript

Nov 19, 2025, 12:30 PM EST - 3 months ago

Why Is Agios Pharmaceuticals Stock Sinking Today?

Nov 19, 2025, 8:24 AM EST - 3 months ago

Agios Pharma reports mixed results in late-stage study for sickle cell disease drug

Nov 19, 2025, 7:00 AM EST - 3 months ago

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

Nov 4, 2025, 1:47 AM EST - 3 months ago

Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones

Nov 3, 2025, 9:01 AM EST - 4 months ago

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

Oct 30, 2025, 2:06 PM EDT - 4 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 6:30 AM EDT - 4 months ago

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 17, 2025, 8:15 AM EDT - 4 months ago

Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia

Oct 17, 2025, 8:00 AM EDT - 4 months ago

Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

Oct 16, 2025, 7:00 AM EDT - 4 months ago

Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET

Sep 18, 2025, 5:49 AM EDT - 5 months ago

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

Sep 15, 2025, 12:20 PM EDT - 5 months ago

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm

Sep 8, 2025, 10:32 AM EDT - 6 months ago

Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive

Sep 4, 2025, 12:46 PM EDT - 6 months ago

Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated

Sep 4, 2025, 10:49 AM EDT - 6 months ago

FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use

Sep 4, 2025, 7:00 AM EDT - 6 months ago

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Aug 4, 2025, 4:01 PM EDT - 7 months ago

Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Jul 31, 2025, 5:02 PM EDT - 7 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 6:30 AM EDT - 7 months ago

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 14, 2025, 7:00 AM EDT - 8 months ago

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

Jul 8, 2025, 7:00 AM EDT - 8 months ago

Agios Appoints Dr. Jay Backstrom to Board of Directors

Jun 9, 2025, 8:40 AM EDT - 9 months ago

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

May 28, 2025, 7:00 AM EDT - 9 months ago

Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

May 14, 2025, 10:00 AM EDT - 10 months ago

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

May 9, 2025, 7:00 AM EDT - 10 months ago

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

May 2, 2025, 7:00 AM EDT - 10 months ago

Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

May 1, 2025, 12:06 PM EDT - 10 months ago

Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript

May 1, 2025, 6:30 AM EDT - 10 months ago

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 17, 2025, 7:00 AM EDT - 11 months ago

Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

Mar 5, 2025, 5:52 PM EST - 1 year ago

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Mar 4, 2025, 7:00 AM EST - 1 year ago

Agios to Present at Upcoming Investor Conferences

Feb 20, 2025, 7:00 AM EST - 1 year ago

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Feb 13, 2025, 1:32 PM EST - 1 year ago

Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 6:31 AM EST - 1 year ago

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 13, 2025, 6:30 AM EST - 1 year ago

Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

stu4 Feb. 23 at 11:04 AM

$AGIO another loser , chasing biotech misfits at AGIOS

0 · Reply

StockConsultant Feb. 23 at 4:22 AM

$AGIO Agios Pharmaceuticals stock, strong close, watch for an upside gap breakout at https://stockconsultant.com/?AGIO

0 · Reply

Dkll303 Feb. 21 at 11:50 AM

$AGIO good thing you clarified your synopsis. Bellevenue sold out of this pos, after 6 years , 3.9M shares A 40M dollar loss !!!

0 · Reply

OfficialStocktwitsUser Feb. 20 at 10:54 PM

0 · Reply

stu4 Feb. 19 at 2:09 PM

0 · Reply

BillionerOfKing Feb. 19 at 10:37 AM

0 · Reply

freddie04 Feb. 13 at 7:26 PM

$AGIO ahhhhh , ohhhhh looks like FOUSE LIED TO SHAREHOLDERS ONCE AGAIN … They need more money to keep their jobs and SUCK YOU DRY with NO VALUE EVER CREATED FOR YOU SHAREHOLDERS

0 · Reply

freddie04 Feb. 13 at 7:24 PM

0 · Reply

freddie04 Feb. 13 at 7:22 PM

$AGIO NO WE HAVE THIS 2/12/26 stated in 2022 “ plenty of cash “ several years is a decade , NOT 4 years They are losers here

0 · Reply

freddie04 Feb. 13 at 7:21 PM

$AGIO ONCE A LIAR, ALWAYS A LIAR FOUSE On RAISING CASH !

0 · Reply

freddie04 Feb. 13 at 5:33 PM

$AGIO with a mixed shelf prospectus filed by 5 PM after earnings ….ya sign me up for dilution !!! @ZacksResearch , lol You morons You forgot this ⬇️ tidbit in your post !!! Hahahahaha

0 · Reply

ZacksResearch Feb. 13 at 4:38 PM

$AGIO just flipped the script with a surprise beat 💥 Agios Pharmaceuticals delivered a narrower-than-expected Q4 loss and beat estimates on both the top and bottom lines, fueled by a 49% year over year jump in Pyrukynd sales. That kind of growth momentum matters. Discover what’s driving the turnaround 👉 https://www.zacks.com/stock/news/2869071/agios-pharmaceuticals-incurs-narrower-than-expected-q4-loss?cid=sm-stocktwits-2-2869071-teaser-33593&ADID=SYND_STOCKTWITS_TWEET_2_2869071_TEASER_33593

0 · Reply

ZacksResearch Feb. 13 at 3:38 PM

$AGIO Q4: Narrower Loss, Revenue Beat, but Stock Down 15.7% Over the Past Year 📉 Agios posted a Q4 loss of $1.85/share vs. Zacks Consensus of $1.97, with revenue hitting $20M, beating expectations. Yet, the stock trails the industry's 17.9% gain. Full earnings scoop here 👉 https://www.zacks.com/stock/news/2869071/agios-pharmaceuticals-incurs-narrower-than-expected-q4-loss?cid=sm-stocktwits-2-2869071-body-33591&ADID=SYND_STOCKTWITS_TWEET_2_2869071_BODY_33591

0 · Reply

Dkll303 Feb. 13 at 2:14 PM

$AGIO no oncology exists with AGIO !!! Morons @StrategicGuidance

0 · Reply

Dkll303 Feb. 13 at 1:02 PM

$AGIO it is now clear why Bellevenue DUMPED ALL THEIR SHARES , 3.7

0 · Reply

Dkll303 Feb. 13 at 12:56 PM

$AGIO to embarrassed is mgmt , to disclose , lol, their prospectus, since it is: Dilution , Fouse said would “never happen again” Goff a mere puppet to replace the liar , Fouse

0 · Reply

Dkll303 Feb. 13 at 12:54 PM

$AGIO hey @kikmontero ….your illustrious company , I see filed at 5PM , 2/12/26 to dilute you , so they can keep their jobs on your dime !!!! You get the shaft at dilution , they , the misfits keep sucking down a salary, never to turn a profit for the foreseeable future . Milanova can’t sell KoolAide to 5 year olds . GOff lies about liver results , after submission. FOUSE ..” we will never need to dilute thru offering after our Servier sale of oncology. “ Another liar !!! Have a comeback , you loser @kikmontero

0 · Reply

stu4 Feb. 13 at 12:49 PM

$AGIO read it and weep , losers here !!!! The mgmt sees no possible way to create value, nor revenue for the welfare office to continue . They used all of Chris Snowden’s discoveries and sold them for cash . That cash is going fast !!!

1 · Reply

stu4 Feb. 13 at 12:46 PM

$AGIO Follow up !! Hahahahahahahaha …told you all they are misfits of the biotech world

0 · Reply

stu4 Feb. 13 at 12:44 PM

$CADL …you were just outed as a fool AGIOS …( $AGIO ) FLIES FOR A SHELF OFFERING YOUR DIP SHIT COMPANY OF TAK and HIS BUFFOONS IS NEXT

2 · Reply

stu4 Feb. 13 at 12:43 PM

$AGIO th LIES CONTINUE HERE GOFF ..with the “ oh we have a liver problem , after the submission went it …STOCK SAW 50% DECLINE …12/24 FOUSE …” no more reason to raise cash “ Agios “ FILES A SHELF OFFERING 2/12/2026 “ Dog shit mgmt ,,,,,, sees they can’t make a go of it All avenues of new MONEY …GONE … They milked the oncology, auctioned off that part of your business for cash, “ to never come back to the market to raise money “ Dumb fcuks here and liars A TRUMP ADMINISTRATION IN CAMBRIDGE, MASS

0 · Reply

stu4 Feb. 12 at 8:29 PM

$AGIO ROT GUT WAINWRIGHT, just put a target of $65 on this POS Their old target price was $98 in July 2021, IT NEVER MADE IT. IT WENT TO $16.95 , FOUSE was CEO , hahaha So they hve shaved 33 dollars off the MC . BUFFOONS

1 · Reply

Market Cap	1.71B
Revenue (ttm)	54.03M
Net Income (ttm)	-412.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-763.98%
Debt to Equity Ratio	0.00

Volume	1,066,200
Avg Vol	1,189,604
Day's Range	N/A - N/A
Shares Out	58.59M
Stochastic %K	95%
Beta	0.91
Analysts	Strong Sell
Price Target	$38.12